Roles
- Assistant Professor of Clinical Medicine
-
Biography
Dr. Mark Anthony Jara is an endocrinologist based in Miami, FL. He graduated from the Universidad Nacional De Asuncion Facultad de Ciencias Medicas medical school and completed his residency in internal medicine at the University of Buffalo. He then pursued a fellowship in endocrinology, diabetes, and metabolism at the University of Miami Johnson Medical School. Dr. Jara is known for his extensive experience in treating conditions such as Osteoporosis & Screening, Thyroid Disorders, and Neuroendocrine Tumors. He is affiliated with Jackson Memorial Hospital and has received high patient ratings for his care. -
Education & Training
Education
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Precision Meets Compassion: Sylvester Launches New Pheochromocytoma and Paraganglioma Clinic
The Miller School at ENDO 2025
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 2 clinical trials.
-
This is a randomized, placebo-controlled, multi-center study. The study includes a Screening Period of up to 12 weeks. After the Screening Period, subjects will be randomly assigned in a 1:1 ratio to receive either paltusotine or placebo. At the end of the Treatment Period, subjects, who in the opinion of the Investigator, may benefit from treatment with paltusotine, may be enrolled in a long-term open-label extension (OLE) for up to 96 weeks. During the OLE, all subjects will receive paltusotine.
- Principal Investigator: Mark Jara
- Study Phase: Phase III
- Enrollment Status: Closed
-
This Phase 2 study aims to evaluate the safety and efficacy of IMVT-1402, a novel FcRn inhibitor, in patients with Graves' disease who have elevated thyroid-stimulating hormone receptor (TSHR) antibodies. The scientific rationale is based on IMVT-1402's mechanism of blocking FcRn-mediated recycling of IgG autoantibodies, as well as previously demonstrated proof-of-concept data from batoclimab, a similar FcRn inhibitor. The study will enroll patients with confirmed Graves' disease who are either overtly or subclinically hyperthyroid and have significantly elevated TSHR antibodies (3× ULN), a population in which reducing pathogenic autoantibodies could potentially modify disease progression.
- Principal Investigator: Mark Jara
- Study Phase: TBD
- Enrollment Status: Open